Provided by Tiger Trade Technology Pte. Ltd.

Galmed Pharmaceuticals

4.12
+0.19404.94%
Post-market: 4.01-0.1090-2.65%16:28 EDT
Volume:14.51K
Turnover:59.30K
Market Cap:4.29M
PE:-0.26
High:4.22
Open:3.97
Low:3.94
Close:3.93
52wk High:13.20
52wk Low:3.29
Shares:1.04M
Float Shares:1.01M
Volume Ratio:1.53
T/O Rate:1.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-16.1401
EPS(LYR):-19.1292
ROE:-72.12%
ROA:-33.45%
PB:0.31
PE(LYR):-0.22

Loading ...

Galmed Pharmaceuticals Effects 1-for-8 Reverse Stock Split

Reuters
·
20 mins ago

Galmed Adjourns Annual Shareholder Meeting to Sept. 3 After Lack of Quorum

Reuters
·
33 mins ago

Galmed Pharmaceuticals Ltd Expected to Post a Loss of $3.12 a Share - Earnings Preview

Reuters
·
Aug 24

Galmed Amends AGM Proxy Materials Ahead of Sept. 2 Shareholder Vote

Reuters
·
Aug 20

Colospan completes feasibility study of new assesment platform

TIPRANKS
·
Aug 19

Galmed Says Colospan Intraoperative Colon Tissue Assessment Study Meets Feasibility Goal in First-in-Human Trial

Reuters
·
Aug 19

Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology

THOMSON REUTERS
·
Aug 19

Galmed trading halted, news pending

TIPRANKS
·
Aug 19

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Reuters
·
Aug 19

Galmed reports results from study of a combination of Aramchol and Xtandi

TIPRANKS
·
Aug 17

Galmed Says Aramchol-Xtandi Combo Lifts Prostate Cancer Cell Death 3-4 Fold in Preclinical Study

Reuters
·
Aug 17

Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (Xtandi®) Alone in Prostate Cancer Models

THOMSON REUTERS
·
Aug 17

Galmed Pharmaceuticals to Execute 1-for-8 Reverse Share Split Aug. 19, 2026

Reuters
·
Aug 15

Galmed Pharmaceuticals Wins Nasdaq Extension to Regain $1 Bid Price Compliance

TIPRANKS
·
Aug 01

Galmed Pharmaceuticals: as a Result of Termination, All Rights to Licensed Technology Will Revert to Yissum

THOMSON REUTERS
·
Jul 30

Galmed Pharmaceuticals: Co's Unit's Obligation to Fund Ongoing Patent Expenses Relating to Licensed Patents Will Cease Effective July 31

THOMSON REUTERS
·
Jul 30

Galmed Pharmaceuticals: Co's Unit & Yissum Entered into Mutual Termination Letter to Terminate License Agreement, Dated June 28, 2021

THOMSON REUTERS
·
Jul 30

Galmed’s Aramchol ODF formulation shows positive results in Parkinson’s

TIPRANKS
·
Jul 28

Galmed Says Aramchol Oral Film Boosts Bioavailability 150%, CNS Exposure 300% in Parkinson’s Program

Reuters
·
Jul 28

Galmed Pharmaceuticals Unveils Cardiac-Targeted Aramchol LNP Breakthrough

TIPRANKS
·
Jul 17